GSK makes $10.6bn cancer bet with Nuvalent acquisition

Traders Union
All News
Financial News
GSK acquires Nuvalent for $10.6bn

Highlights

GSK acquires Nuvalent for $10.6bn, securing two late-stage lung cancer drugs to strengthen its oncology pipeline under CEO Miels.
The Nuvalent deal aims to help GSK achieve its 40 billion pound annual revenue target by 2031 and offset future dolutegravir patent expiries.
GSK shares have risen more than 8% since Miels became CEO, indicating investor approval of his strategy despite continued competition from larger rivals like AstraZeneca.

Leadership strategy behind the Nuvalent deal

As reported by the Financial Times, the acquisition marks the biggest move so far by Miels, a former AstraZeneca executive who took over as GSK chief executive after Dame Emma Walmsley stepped down last year.

People who have worked with him describe him as commercially driven and willing to act decisively, rather than pursue small incremental steps. That approach is now visible in a transaction that gives GSK two late-stage lung cancer drugs that Miels says have the potential to be best in class.

Miels joined GSK nine years ago after a contentious exit from AstraZeneca, where he had been seen as a senior lieutenant to chief executive Sir Pascal Soriot. That departure led to a legal dispute before both sides reached an out-of-court settlement, and executives familiar with the matter say the relationship has since recovered.

Colleagues describe Miels as low-key and non-hierarchical, but also forceful in investment decisions. During his time as GSK’s commercial chief, he spent significant effort identifying acquisition targets, and that focus appears to be continuing in his current role.

Oncology growth targets and competitive pressure

The Nuvalent acquisition is a significant test of GSK’s strategy to become a more serious competitor in oncology, an area that remains crowded, highly competitive and financially attractive. GSK has historically relied on smaller deals in cancer, but those moves have not been enough to place the company among the sector’s leading players.

The deal also supports GSK’s target of generating more than 40 billion pounds in annual revenue by 2031. Oncology growth is expected to help offset the impact of future patent expiries for dolutegravir, GSK’s best-selling HIV medicine, which accounted for nearly 20% of revenue last year.

Investors appear to welcome the early direction under Miels, with GSK shares up more than 8% since he took office. Even so, the company still faces a demanding task as it tries to close the gap with larger rivals, including AstraZeneca, which remains significantly bigger than GSK.

Our earlier article on Eli Lilly (LLY) price action highlighted that the stock remains in a broader bullish trend, even after a notable daily drop and signs of overbought conditions. It also pointed to key catalysts such as progress in GLP-1/obesity treatments and expanding AI partnerships, while noting that some institutional selling could signal near-term volatility for traders.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.